Rare diseases
Investigational molecules
Locations
Study of Vemurafenib and Rituximab for Untreated Hairy Cell Leukemia Patients
ItalyStudy on the Effectiveness of Tepotinib and Drug Combination for Patients with Advanced Cancer
NorwayStudy on the Safety of Encorafenib, Binimetinib, and Ribociclib for Patients with Solid Tumors
CzechiaStudy of Vemurafenib, Cobimetinib, and Atezolizumab for Patients with High-Risk, Surgically Removable BRAF Mutated and Wild-Type Melanoma
ItalyStudy of Drug Combination for Advanced Cancer Patients with Known Molecular Profile - FINPROVE Study
FinlandStudy on the Effectiveness of Entrectinib and Other Drug Combinations for Patients with Advanced Solid Tumors, Multiple Myeloma, or Non-Hodgkin Lymphoma
The NetherlandsStudy of drug combination in patients with advanced cancer based on genomic profiling - ProTarget Danish nationwide trial
DenmarkStudy of Obinutuzumab, Vemurafenib, and Cobimetinib for Hairy Cell Leukemia in Patients Previously Treated with Purine Analogs or Unfit for Chemotherapy
ItalyStudy on Vemurafenib for Children with BRAF Mutation-Resistant Histiocytosis
PolandStudy on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials
BelgiumStudy on Vemurafenib for Patients with Advanced Cancers with BRAF Gene Changes
FranceTell us about your condition – we search every trial in Europe and connect you with the right site.
